Grant: Catalyst Gr: Cann Res in Urgent Areas-Cannabis in the context of pain management
Université Laval
$124,954.00
Medical cannabis against chronic musculoskeletal pain - a mixed methods study to describe use and to identify its facilitators and barriers among Canadian patients and doctors.
FY 2018-19
Summary
It is currently impossible to make appropriate recommendations as to the use of medical cannabis against chronic musculoskeletal pain (CMP), because this question has not been studied sufficiently. Nevertheless, many Canadians suffering from such pain turn to medical cannabis for treatment. Little is known about these users of medical cannabis, as well as about the doctors prescribing it. Knowledge about use of medical cannabis against CMP in Canada would help to inform or educate users and prescribers, and it would be a first step to a user focused program of research on medical cannabis against CMP.
Our project will document:
1-How many Canadians are using cannabis against CMP and what are their characteristics?
2-Why are Canadian physicians prescribing or not prescribing medical cannabis against CMP ?
3-What are the known therapeutic and adverse effects of medical cannabis from the users' and physicians' perspective?
We will use four sources of information: 1) the Quebec Cannabis Registry, 2) the database on medical cannabis of Health Canada, 3) a sample of patients with CMP, including current users of medical cannabis, and 4) a sample of physicians who prescribe or not medical cannabis. This will allow us to describe the recent use of medical cannabis in Canada, its positive and negative effects on CMP according to patients and physicians, and to identify which characteristics of patients and physicians make a difference.
While cannabis seems to be an interesting option for the relief of CMP, it is currently difficult to conduct rigorous randomized clinical trials (RCT) on this topic, because of major methodological and ethical problems. This study will make an essential contribution to knowledge by gathering the currently available information from different sources, and by developing adapted approaches to address the specific challenges of RCTs in this area. These results will eventually lead to clear answers about the utility of medical cannabis against CMP.
Department
Program
Catalyst Gr: Cann Res in Urgent Areas-Cannabis in the context of pain management
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
404019
Name
Kroger Edeltraut
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Cannabis Research in Urgent Priority Areas
Projecttitle
Medical cannabis against chronic musculoskeletal pain - a mixed methods study to describe use and to identify its facilitators and barriers among Canadian patients and doctors.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$124,954
Cihrequipment2
$0
Programname2
Catalyst Gr: Cann Res in Urgent Areas-Cannabis in the context of pain management
Keyworddelim
Canadian Prescribers; Canadian Users; Medical Cannabis; Mixed Methods; Musculoskeletal Pain; Quebec Cannabis Registry
Abstract
It is currently impossible to make appropriate recommendations as to the use of medical cannabis against chronic musculoskeletal pain (CMP), because this question has not been studied sufficiently. Nevertheless, many Canadians suffering from such pain turn to medical cannabis for treatment. Little is known about these users of medical cannabis, as well as about the doctors prescribing it. Knowledge about use of medical cannabis against CMP in Canada would help to inform or educate users and prescribers, and it would be a first step to a user focused program of research on medical cannabis against CMP.
Our project will document:
1-How many Canadians are using cannabis against CMP and what are their characteristics?
2-Why are Canadian physicians prescribing or not prescribing medical cannabis against CMP ?
3-What are the known therapeutic and adverse effects of medical cannabis from the users' and physicians' perspective?
We will use four sources of information: 1) the Quebec Cannabis Registry, 2) the database on medical cannabis of Health Canada, 3) a sample of patients with CMP, including current users of medical cannabis, and 4) a sample of physicians who prescribe or not medical cannabis. This will allow us to describe the recent use of medical cannabis in Canada, its positive and negative effects on CMP according to patients and physicians, and to identify which characteristics of patients and physicians make a difference.
While cannabis seems to be an interesting option for the relief of CMP, it is currently difficult to conduct rigorous randomized clinical trials (RCT) on this topic, because of major methodological and ethical problems. This study will make an essential contribution to knowledge by gathering the currently available information from different sources, and by developing adapted approaches to address the specific challenges of RCTs in this area. These results will eventually lead to clear answers about the utility of medical cannabis against CMP.
Competitiondate
201810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kroger, Edeltraut; Dionne, Clermont
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $124,954~ $0~